Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Starpharma Holdings' dendrimer-docetaxel formulation applying its dendrimer technology was found to be more efficacious than docetaxel (Taxotere) alone in a breast cancer model.
Subscribe to our email newsletter
Docetaxel, marketed by Sanofi Aventis as Taxotere is a leading chemotherapy drug used to treat a variety of solid tumors including breast, lung and prostate.
As part of its drug delivery program for docetaxel, the company has conducted the latest study, a breast cancer xenograft in mice to evaluate the efficacy of dendrimer-docetaxel formulations in treating cancer.
The study demonstrated that dendrimer-docetaxel formulation showed a significant improvement of anticancer effect when compared to docetaxel/Taxotere alone.
Starpharma CEO Jackie Fairley said the initial results of their dendrimer-docetaxel program showed no evidence of tumors and a significant improvement in efficacy versus docetaxel in a high proportion of animals.
”These findings together with the ability of Starpharma’s dendrimers to markedly improve water solubility represent a compelling product proposition," Fairley added.